

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number		10/522,401	
				Filing Date		January 19, 2005	
				First Named Inventor		Taishi YOSHIDA	
				Group Art Unit		1646	
				Examiner Name			
Sheet	1	of	3	Attorney Docket Number		04818CIP/HG	

U.S. PATENT DOCUMENTS

Exam. Inits ¹	Cite No ¹	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion

FOREIGN PATENT DOCUMENTS

Exam Inits ¹	Cite No ¹	Offc ³	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶
/M.F./		WIPO	WO 01/47935	A2	Metabasis Ther.	07-05-2001		
/M.F./		WIPO	WO 99/47549	A1	Ontogen Corp.	09-23-1999		

Examiner Signature	/Meghan Finn/	Date Considered	06/30/2007
-----------------------	---------------	--------------------	------------

¹ EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Place a check here if English translation is attached.

DATE MAILED: May 3, 2005

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number		10/522,401	
				Filing Date		January 19, 2005	
				First Named Inventor		Taishi YOSHIDA	
				Group Art Unit		1646	
				Examiner Name			
Sheet	2	of	3	Attorney Docket Number		04818CIP/HG	
OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published					T ²
/M.F./		WRIGHT, et al., "Anilinoquinazoline Inhibitors of Fructose-1,6-Bisphosphatase Bind at a Novel Allosteric Site: Synthesis, In Vitro Characterization, and X-ray Crystallography", <u>J. Med. Chem.</u> , 29 August, 2002 (29.08.02); 45(18): 3865-77					
/M.F./		WRIGHT, et al., "Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazo lines.", <u>Bioorg. Med. Chem. Lett.</u> , 08 January 2001 (08.01.01); 11(1):17-21					
/M.F./		KNOWLER, et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.", <u>N. Engl. J. Med.</u> , 07 February 2002 (07.02.02); 346(6):393-403.					
/M.F./		SARTOR, et al., "Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation.", <u>Diabetes</u> , 1980 January; 29(1):41-9.					
/M.F./		NOLAN, et al., "Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.", <u>N. Engl. J. Med.</u> , 03 November 1994 (03.11.94); 331(18):1188-93.					
/M.F./		ANTONUCCI, et al., "Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.", <u>Diabetes Care</u> , 1997 February; 20(2):188-93.					
Examiner Signature		/Meghan Finn/			Date Considered		06/30/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: May 3, 2005

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number		10/522,401	
				Filing Date		January 19, 2005	
				First Named Inventor		Taishi YOSHIDA	
				Group Art Unit		1646	
				Examiner Name			
Sheet	3	of	3	Attorney Docket Number		04818CIP/HG	
OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published					T ²
/M.F./		English translation of International Preliminary Examination Report Form PCT/IPEA/409 in International Application No. PCT/JP2003/009348					
/M.F./		YAMASAKI et al., "Asymptomatic Hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery", <u>Diabetologia</u> , 1995; 38:585-591					
/M.F./		TOMINAGA et al., "Impaired Glucose Tolerance Is a Risk Factor for Cardiovascular Disease, but Not Impaired Fasting Glucose", <u>Diabetes Care</u> , 1999, 22:920-924					
/M.F./		Journal of Japan Diabetes Society 1999; 42(5):385-404 (English Abstract is attached on pages 402-404)					
/M.F./		"REPORT OF THE EXPERT COMMITTEE ON THE DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS", <u>Diabetes Care</u> , 1997; 20:1183-1197					
/M.F./		ALBERTI, et al., "Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications", <u>Diabetic Medicine</u> , 1998; 15:539-553					
/M.F./		HOTTA et al., "The inhibitory action of buformin, a biguanide on gluconeogenesis from alanine and its transport system in rat livers", <u>Diabetes Research and Clinical Practice</u> , 1993,19:49-58					
Examiner Signature		/Meghan Finn/			Date Considered		06/30/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: May 3, 2005

10/522401

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box →

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number		105 Rec'd PCT/PTO 19 JAN 2005	
				Filing Date		Herewith	
				First Named Inventor		Taishi YOSHIDA	
				Group Art Unit			
				Examiner Name			
Sheet	1	of	2	Attorney Docket Number		04818CIP/HG	

U.S. PATENT DOCUMENTS

Exam. Inits [*]	Cite No ¹	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion

FOREIGN PATENT DOCUMENTS

Exam Inits [*]	Cite No ¹	Offc ³	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶
/M.F./		WIPO	WO 01/47935	A2	Metabasis Ther.	07-05-2001		
/M.F./		WIPO	WO 99/47549	A1	Ontogen Corp.	09-23-1999		

Examiner Signature	/Meghan Finn/	Date Considered	06/30/2007
-----------------------	---------------	--------------------	------------

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.

DATE MAILED: January 19, 2005

10/522401

DT05 Rec'd PCT/PTO 19 JAN 2005

PTO/SB/08B (08-00)

Please type a plus sign (+) inside this box →



U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number			
				Filing Date		Herewith	
				First Named Inventor		Taishi YOSHIDA	
				Group Art Unit			
				Examiner Name			
Sheet	2	of	2	Attorney Docket Number		04818CIP/HG	
OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published					T ²
/M.F./		WRIGHT, et al., "Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazo lines.", <u>J. Med. Chem.</u> , 29 August, 2002 (29.08.02); 45(18): 3865-77					
/M.F./		WRIGHT, et al., "Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazo lines.", <u>Bioorg. Med. Chem. Lett.</u> , 08 January 2001 (08.01.01); 11(1):17-21					
/M.F./		KNOWLER, et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.", <u>N. Engl. J. Med.</u> , 07 February 2002 (07.02.02); 346(6):393-403. (abstract) Medline (PubMed) [online], PMID 11832527					
/M.F./		SARTOR, et al., Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation.", <u>Diabetes</u> , 1980 January; 29(1):41-9. (abstract) Medline (PubMed) [online], PMID 7380107					
/M.F./		NOLAN, et al., "Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.", <u>N. Engl. J. Med.</u> , 03 November 1994 (03.11.94); 331(18):1188-93. (abstract) Medline (PubMed) [online], PMID 7935656					
/M.F./		ANTONUCCI, et al., "Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.", <u>Diabetes Care</u> , 1997 February; 20(2):188-93. (abstract) Medline (PubMed) [online], PMID 9118772					
Examiner Signature		/Meghan Finn/			Date Considered	06/30/2007	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Place a check here if English translation is attached.

DATE MAILED: January 19, 2005